**S4.. The number of patients receiving no treatment or different types of first-line palliative chemotherapy and biologics.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Regimens** | **50–69 years**  **N = 338** | | **70–89 years**  **N = 316** | |
|  | Number | % | Number | % |
| No treatment | 35 | 10.4 | 62 | 19.6 |
| Capecitabine | 6 | 1.8 | 42 | 13.3 |
| Irinotecan | 5 | 1.5 | 25 | 7.9 |
| Capecitabine/5-FU + oxaliplatin | 124 | 36.6 | 107 | 33.8 |
| Capecitabine/5-FU + irinotecan | 38 | 11.3 | 16 | 5.0 |
| Capecitabine/5-FU + bevacizumab | 3 | 0.9 | 5 | 1.6 |
| Capecitabine/5-FU + oxaliplatin + bevacizumab | 48 | 14.2 | 36 | 11.3 |
| Capecitabine/5-FU + irinotecan + bevacizumab | 44 | 13.1 | 10 | 3.2 |
| 5-FU + oxaliplatin + cetuximab | 24 | 7.2 | 11 | 3.4 |
| 5-FU + irinotecan + cetuximab | 7 | 2.1 | 0 | - |
| Other | 4 | 1.2 | 2 | 0.6 |